UCB beats street with new-drug growth; Mylan to sell $300M in debt for Bioniche deal;

 @FiercePharma: Why does Sanofi's CEO consider 'patent' a dirty word? Report | Follow @FiercePharma

> Belgium's UCB (UCB.BR) reported better than expected first-half results after sales of new drugs accelerated, offsetting declines in blockbusters now facing generic competition. Report

> Generic drugmaker Mylan has priced $300 million in senior notes due in 2020, to help pay for its $550 million acquisition of Bioniche Pharma Holdings. Story

> Generic drugmakers are fighting back against new moves in Congress to ban pay-for-delay deals with branded drugmakers. News

> Merck had indicated that its vaccine Recombivax would ship in mid-2010 after manufacturing issues disrupted supplies, but now the company indicates the vaccine won't be available at all this year. Article

> Teva Pharmaceutical Industries said Canadian antitrust regulators have cleared the company's acquisition of Ratiopharm, owned by the Merckle family. News

> KV Pharmaceutical sued generics maker Perrigo, alleging patent infringement with plans to make low-cost copies of the drug Gynazole used to treat female yeast infections. Report

Biotech News

 @FierceBiotech: Charles River, WuXi call off $1.6B deal. Report | Follow @FierceBiotech

 @JohnCFierce: Isis says liver enzymes spike when you lower cholesterol; with statins or mipomersen. Could that fly at FDA? I doubt it. | Follow @JohnCFierce

> Wall Street handicaps Sanofi's looming Genzyme bid. Story

> Isis, Genzyme brace for new round of late-stage cholesterol data. Report

> Cardioxyl gets $15M and positive data on lead program. Article

Biotech IT news

> Informatics app matches biosamples, projects. Report

> CRO lightens RA publishing load via SharePoint. News

> Omnicomm buoyed by e-clinical licensing deals. Report

And Finally... The FDA approved vaccines for the next flu season and recommended vaccination for everyone but small infants. Story